“Nuclear medicine is entering a new era in which imaging is expected to do more than identify disease – it is increasingly being used to quantify biological processes, support treatment decisions and monitor response to therapy,” GE HealthCare Molecular Imaging Executive Director Erez Levy said in the announcement.
“By working across multiple regions and care environments, we aim to generate clinical and research insights that can help inform innovation as imaging, quantitation and workflow needs evolve,” he said.
The five internationally recognized programs are Mayo Clinic (US), Hadassah Medical Center (Israel), Oncopole Claudius Regaud – Institut Universitaire du Cancer de Toulouse (France), Peking University First Hospital (China) and Rambam Health Care Campus (Israel).
These programs will evaluate the GE HealthCare StarGuide GX 4D SPECT/CT system for image quality, quantitative performance, dynamic imaging and workflow. They’ll provide clinical and research-driven feedback to advance the next generation of theranostic imaging technology.
Related: GE HealthCare and Mayo Clinic collaborate on novel cancer treatment research study
Each participating program will evaluate the platform from different care settings. Mayo Clinic will evaluate advanced quantitative and dynamic imaging applications, while other institutions will focus on areas such as SPECT/CT platforms in routine oncology imaging and clinical research; explore novel tracer research and preclinical applications; and StarGuide GX’s imaging workflows.
StarGuide GX utilizes dual-sided cadmium zinc telluride detector technology to produce high-sensitivity, high-resolution imaging and wuantititative imaging, the company says.
The system’s configuration enables the detectors to move close to the patient during. Its dual-collimator detector design is intended to eliminate manual external collimator exchanges and streamline imaging workflows, GE Healthcare says.
Related: GE HealthCare’s on-site cyclotron for PET agent production claims CE Mark
“The system’s ergonomic design and flexibility have the potential to significantly improve workflow while supporting precision in quantitative imaging and high-energy radionuclide applications,” Courbon said. “Our first experience suggests that StarGuide GX represents a meaningful step forward in enabling advanced theranostic practices.”
StarGuide GX supports a wide energy range of radionuclides, and in research settings, the system could help evaluate imaging radionuclides associated with emerging alpha-emitter research and further expand theranostic applications.
The collaborations advance GE HealthCare’s work with University Hospital Essen in Germany, which was the site of the first StarGuide GX SPECT/CT installation. The next-generation theranostic imaging system received CE Mark in November 2025 and is awaiting 510(k) clearance with FDA.
